A CDC analysis of 2022 data finds that U.S. life expectancy is improving after being knocked backwards during the COVID emergency. But it's still lower than it was pre-pandemic.
After 40 years of living and travelling together, a writer considers a trip without his wife. He can't explain where he's going or why he can't bring her along.
A new citizen-scientist research project aims to test whether daily moments of awe, kindness and gratitude can make a real impact. Early results are promising. And it's not too late to join the study.
Falling is the top cause of injury for older adults and even mild hearing loss can increase the risk. But consistently wearing hearing aids may improve balance and prevent falls, a study finds.
Research shows that a daily dose of tai chi, the slow-moving meditative, martial art can boost our body and brain. A new study finds adding word games to tai chi doubles the increase in memory.
Shields spoke last week at an Atlanta Women’s Foundation luncheon and fundraiser about the importance of empowering women, supporting their education and mental health.
Medicare's annual open enrollment period began Oct. 15, allowing seniors to choose new plans. New rules this year are supposed to crack down on misleading marketing but buyers should still beware.
The Biden administration says a recently proposed minimum staffing standard would help ensure quality care, but nursing home leaders predict it will accelerate a trend of closures in rural America.
A study commissioned by the government to recommend minimum staffing levels at nursing homes drew no conclusions. And that means Biden's pledge to set those minimums may come to far less than hoped.
Fewer than half of older adults who need mental health care or treatment for substance abuse get it. Many therapists don't feel qualified to treat older people, and insurance coverage is spotty, too.
It can be heartbreaking to let go of a hand-made rug or sweater that a loved one didn't quite finish. A group of volunteer knitters, quilters and other crafters offer some closure.
In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.
The Food and Drug Administration is expected to grant full approval to the Alzheimer's drug lecanemab by July 6. But access to the drug may still be limited.
